THE RA 27/3 strain of rubella vaccine isolated from a tissue explant of fetal kidney derived from conceptus of a rubellainfected mother and attenuated after several passages in WI-38 human fibroblast tissue culture has been shown in several clinical trials to be effective for induction of sero-immunity when administered subcutaneously as well as intranasally, with no transmission to sero-negative contacts.1-3 To the best of our knowledge, RA 27/3 has not been used simultaneously with other vaccines. This communication presents our findings on subcutaneous and intranasal administration of RA 27/3 rubella vaccine, alone and in conjunction with live attenuated measles vaccine.
Materials and Methods
Vaccine.—The RA 27/3 rubella vaccine (batch AR/2/2A) was obtained with 102.8 TCID50 titer by monkey kidney interference method. Measles vaccine (Schwarz strain) in 20 dose vials with the titer of 102.8 TCID50 in chick embryo fibroblast was used.Antigens.—Measles and
Saidi S, Naficy K. Subcutaneous and Intranasal Administration of RA 27/3 Rubella Vaccine: Alone and in Conjunction With Live Attenuated Measles Vaccine. Am J Dis Child. 1969;118(2):209–212. doi:https://doi.org/10.1001/archpedi.1969.02100040211009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: